The Oral Bet Challenging Today’s GLP 1 Era

Aardvark and Rivus advance early stage metabolic therapies as interest grows beyond GLP 1 drugs and potential new options emerge

8 Dec 2025

A group of emerging biotech companies is exploring oral therapies that could complement, or one day compete with, the injectable GLP-1 drugs that dominate metabolic medicine. The work remains early and uncertain but has drawn close attention from investors and clinicians.

Interest increased after Aardvark Therapeutics released first data on its lead pill. The candidate showed initial signs of weight reduction while maintaining muscle mass, with the effect strengthening when combined with a low dose GLP-1. Analysts noted that the findings come from a small study and require larger trials, but the signal has prompted discussion about possible combination strategies if the results hold. Patients reluctant to use long-term injections may view oral options as more practical, though any commercial impact is unclear.

Other groups are pursuing different routes. Rivus Pharmaceuticals is testing a compound aimed at increasing energy expenditure, though it remains at an early clinical stage. Market speculation continues around Metabolica Health and its microbiome-based research, but the company has released few details and no data to date.

Much of the curiosity reflects how often US patients cycle on and off GLP-1 therapy. The pattern has led investors to consider whether oral add-ons or follow-up treatments could broaden access or support longer-term adherence. Health-policy specialists warn that expectations should remain modest. Insurers continue to assess the long-term cost of obesity drugs, and regulators are likely to seek clear clinical evidence before approving new approaches.

The companies face multiple obstacles, from scientific uncertainty to payer hesitation. Yet the early flow of research points to a wider attempt to diversify the tools available for metabolic disorders.

With more trial results expected in the coming years, the sector’s trajectory will depend on clinical performance and regulatory scrutiny. Success could expand treatment choices for patients, but for now the programmes remain early-stage experiments under careful review.